Physiomics awarded grant for PREDICT-ONC project in precision oncology

Physiomics plc, a leader in mathematical modelling and drug development, announces its latest achievement: securing a grant for the PREDICT-ONC project. This project, funded by Innovate UK and The Office for Life Sciences, is part of the UK Government’s Advancing Precision Medicine programme, spotlighting Physiomics’ commitment to oncology research and personalised medicine.

PREDICT-ONC: A Leap in Neutropenia Treatment and Diagnosis

The PREDICT-ONC project, a collaboration with Beyond Blood Diagnostics Limited and Blackpool Teaching Hospitals NHS Foundation Trust, focuses on addressing the clinical challenges in chemotherapy-induced neutropenia. Total project costs are £570,651, with Physiomics shouldering £196,251, primarily for staff salaries. The project, 70% funded by the grant, will grant Physiomics £137,376 over its duration, starting immediately and running until October 2025.

Building on Previous Achievements in Personalised Oncology

The project aims to further develop Physiomics’ personalised dosing tool, previously funded by grants from Innovate UK and the National Institute for Health and Care Research. Focusing on docetaxel-treated cancers, PREDICT-ONC will extend the dosing tool to include clinical decision-making around G-CSF dosing.

Physiomics secures grant from UK government for PREDICT-ONC project in precision oncology

Innovative Clinical Trials to Enhance Cancer Treatment

Led by Prof. Francis Martin, the observational clinical trial under PREDICT-ONC will rigorously monitor patients during chemotherapy. Blackpool’s NIHR-funded Patient Recruitment Centre and Beyond Blood Diagnostics’ point-of-care tool will play pivotal roles in the trial, potentially transforming neutropenia diagnosis and management.

Collaborative Efforts to Revolutionize Cancer Care

Physiomics CEO, Dr Jim Millen, expressed enthusiasm for the project, recognizing it as a testament to the company’s innovative spirit. This collaboration aims to significantly advance the approach to neutropenia treatment in cancer care.

About Physiomics plc:

Physiomics, a pioneer in mathematical modelling for oncology drugs and personalised medicine, continues to lead the way in cancer treatment innovation, backed by substantial grants and strong collaborative partnerships.